Exploring the Therapeutic Potential of Β -Hydroxybutyrate (Bhb) in Clear Cell Renal Cell Carcinoma: A Journey Into Fat Browning, Autophagy, and Tumor Slimming Publisher



R Rezaei ROYA ; A Abdali Larki ASRA ; R Hosseinzadegan ROSA ; Z Dashti ZAHRA ; S Tarkashvand SABA ; R Akhoondi REIHANEH ; M Siri MORVARID ; M Shams MESBAH ; A Monsef ALIREZA ; S Dastgheib SANAZ
Source: International Journal of Clinical Practice Published:2024

Abstract

This study delves into the therapeutic potential of β-hydroxybutyrate (BHB) in clear cell renal cell carcinoma (ccRCC), a cancer known for its complex pathogenesis and resistance to conventional treatments. The research specifically explores the impact of BHB on cell viability, autophagy induction, and lipid metabolism in Caki-1 cells. The findings reveal that BHB significantly reduces ccRCC cell viability, particularly under low-glucose conditions. The combination of glucose and BHB treatment activates autophagy pathways, as evidenced by increased expression of autophagy-related genes (Beclin-1, LC3IIβ, and ATG5) and decreased expression of P62 after 48 and 72 hours. Moreover, the combined therapy enhances lipid metabolism, as indicated by elevated expression of PGC-1α and UCP-1, along with upregulation of ACSL3 and CPT1A, which are associated with lipid droplet formation and facilitate lipid breakdown within cells. The study concludes that BHB holds promise as a therapeutic agent for ccRCC, targeting abnormal lipid metabolism, inducing autophagy-mediated cell death, and promoting fat browning. The results suggest potential avenues for precision-guided nutritional therapies in ccRCC treatment, highlighting the innovative role of BHB in addressing the challenges posed by this cancer. © 2024 Elsevier B.V., All rights reserved.